Adverse fibrosis in the aging heart depends on signaling between myeloid and mesenchymal cells; role of inflammatory fibroblasts

Journal of Molecular and Cellular Cardiology

Volumn 70, Issue , 2014, Pages 56-63

  Cieslik, Katarzyna A ^a   Trial, JoAnn ^a   Crawford, Jeffrey R ^a   Taffet, George E ^a   Entman, Mark L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Inflammatory fibroblast; MCP 1; Mesenchymal stem cell; TGF

Indexed keywords

COLLAGEN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

AGING; CELL DIFFERENTIATION; FIBROBLAST; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART MUSCLE; HUMAN; MESENCHYMAL STROMA CELL; METABOLISM; MONOCYTE; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AGING; CELL DIFFERENTIATION; COLLAGEN; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; HUMANS; MESENCHYMAL STROMAL CELLS; MONOCYTES; MYOCARDIUM; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84898828108     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.10.017     Document Type: Review

References (103)

1. Uusimaa P., Risteli J., Niemela M., Lumme J., Ikaheimo M., Jounela A., et al. Collagen scar formation after acute myocardial infarction: relationships to infarct size, left ventricular function, and coronary artery patency. Circulation 1997, 96:2565-2572.
2. Kai H., Mori T., Tokuda K., Takayama N., Tahara N., Takemiya K., et al. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res 2006, 29:711-718.
3. Ashrafian H., McKenna W.J., Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res 2011, 109:86-96.
4. Asbun J., Villarreal F.J. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 47:693-700.
5. Cieslik K.A., Taffet G.E., Carlson S., Hermosillo J., Trial J., Entman M.L. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 2011, 50:248-256.
6. Dewald O., Ren G., Duerr G.D., Zoerlein M., Klemm C., Gersch C., et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004, 164:665-677.
7. Haudek S.B., Xia Y., Huebener P., Lee J.M., Carlson S., Crawford J.R., et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci U S A 2006, 103:18284-18289.
8. Duerrschmid C., Crawford J.R., Reineke E., Taffet G.E., Trial J., Entman M.L., et al. TNF receptor 1 signaling is critically involved in mediating angiotensin-II-induced cardiac fibrosis. J Mol Cell Cardiol 2013, 57:59-67.
9. Langer H.F., Chavakis T. Leukocyte-endothelial interactions in inflammation. J Cell Mol Med 2009, 13:1211-1220.
10. Kawaguchi M., Takahashi M., Hata T., Kashima Y., Usui F., Morimoto H., et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011, 123:594-604.
11. Buckley C.D., Pilling D., Lord J.M., Akbar A.N., Scheel-Toellner D., Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 2001, 22:199-204.
12. Beck-Schimmer B., Schwendener R., Pasch T., Reyes L., Booy C., Schimmer R.C. Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury. Respir Res 2005, 6:61.
13. Denton C.P., Shi-Wen X., Sutton A., Abraham D.J., Black C.M., Pearson J.D. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998, 114:293-300.
14. McGettrick H.M., Smith E., Filer A., Kissane S., Salmon M., Buckley C.D., et al. Fibroblasts from different sites may promote or inhibit recruitment of flowing lymphocytes by endothelial cells. Eur J Immunol 2009, 39:113-125.
15. Carr M.W., Roth S.J., Luther E., Rose S.S., Springer T.A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A 1994, 91:3652-3656.
16. Rollins B.J. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996, 2:198-204.
17. Haudek S.B., Cheng J., Du J., Wang Y., Hermosillo-Rodriguez J., Trial J., et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 49:499-507.
18. Frangogiannis N.G., Dewald O., Xia Y., Ren G., Haudek S., Leucker T., et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007, 115:584-592.
19. Xu J., Lin S.C., Chen J., Miao Y., Taffet G.E., Entman M.L., et al. CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011, 301:H538-H547.
20. Haudek S.B., Trial J., Xia Y., Gupta D., Pilling D., Entman M.L. Fc receptor engagement mediates differentiation of cardiac fibroblast precursor cells. Proc Natl Acad Sci U S A 2008, 105:10179-10184.
21. Trial J., Cieslik K.A., Haudek S.B., Duerrschmid C., Entman M.L. Th1/M1 conversion to Th2/M2 responses in models of inflammation lacking cell death stimulates maturation of monocyte precursors to fibroblasts. Front Immunol 2013, 4:287.
22. Wada T., Furuichi K., Sakai N., Iwata Y., Kitagawa K., Ishida Y., et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol 2004, 15:940-948.
23. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998, 152:423-430.
24. Inoshima I., Kuwano K., Hamada N., Hagimoto N., Yoshimi M., Maeyama T., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1038-L1044.
25. Dewald O., Frangogiannis N.G., Zoerlein M., Duerr G.D., Klemm C., Knuefermann P., et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc Natl Acad Sci U S A 2003, 100:2700-2705.
26. Feinberg M.W., Shimizu K., Lebedeva M., Haspel R., Takayama K., Chen Z., et al. Essential role for Smad3 in regulating MCP-1 expression and vascular inflammation. Circ Res 2004, 94:601-608.
27. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993, 90:770-774.
28. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
29. Frangogiannis N.G., Ren G., Dewald O., Zymek P., Haudek S., Koerting A., et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111:2935-2942.
30. Scholten D., Reichart D., Paik Y.H., Lindert J., Bhattacharya J., Glass C.K., et al. Migration of fibrocytes in fibrogenic liver injury. Am J Pathol 2011, 179:189-198.
31. Chen G., Lin S.C., Chen J., He L., Dong F., Xu J., et al. CXCL16 recruits bone marrow-derived fibroblast precursors in renal fibrosis. J Am Soc Nephrol 2011, 22:1876-1886.
32. Moore B.B., Kolodsick J.E., Thannickal V.J., Cooke K., Moore T.A., Hogaboam C., et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol 2005, 166:675-684.
33. Cieslik K.A., Trial J., Carlson S., Taffet G.E., Entman M.L. Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels. FASEB J 2013, 27:1761-1771.
34. Carlson S., Trial J., Soeller C., Entman M.L. Cardiac mesenchymal stem cells contribute to scar formation after myocardial infarction. Cardiovasc Res 2011, 91:99-107.
35. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
36. Cieslik K.A., Trial J., Entman M.L. Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway. Am J Pathol 2011, 179:1792-1806.
37. Gould K.E., Taffet G.E., Michael L.H., Christie R.M., Konkol D.L., Pocius J.S., et al. Heart failure and greater infarct expansion in middle-aged mice: a relevant model for postinfarction failure. Am J Physiol Heart Circ Physiol 2002, 282:H615-H621.
38. Bujak M., Kweon H.J., Chatila K., Li N., Taffet G., Frangogiannis N.G. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Coll Cardiol 2008, 51:1384-1392.
39. Cieslik K.A., Taffet G.E., Crawford J.R., Trial J., Mejia Osuna P., Entman M.L. AICAR-dependent AMPK activation improves scar formation in the aged heart in a murine model of reperfused myocardial infarction. J Mol Cell Cardiol 2013, 63C:26-36.
40. Silva J., Nichols J., Theunissen T.W., Guo G., van Oosten A.L., Barrandon O., et al. Nanog is the gateway to the pluripotent ground state. Cell 2009, 138:722-737.
41. Liang J., Wan M., Zhang Y., Gu P., Xin H., Jung S.Y., et al. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol 2008, 10:731-739.
42. Xu R.H., Sampsell-Barron T.L., Gu F., Root S., Peck R.M., Pan G., et al. NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in human ESCs. Cell Stem Cell 2008, 3:196-206.
43. Han J., Mistriotis P., Lei P., Wang D., Liu S., Andreadis S.T. Nanog reverses the effects of organismal aging on mesenchymal stem cell proliferation and myogenic differentiation potential. Stem Cells 2012, 30:2746-2759.
44. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
45. ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H., et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993, 8:2879-2887.
46. Ebner R., Chen R.H., Shum L., Lawler S., Zioncheck T.F., Lee A., et al. Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 1993, 260:1344-1348.
47. Franzen P., ten Dijke P., Ichijo H., Yamashita H., Schulz P., Heldin C.H., et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell 1993, 75:681-692.
48. Chambers I., Silva J., Colby D., Nichols J., Nijmeijer B., Robertson M., et al. Nanog safeguards pluripotency and mediates germline development. Nature 2007, 450:1230-1234.
49. Choy L., Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem 2003, 278:9609-9619.
50. Jones D.L., Rando T.A. Emerging models and paradigms for stem cell ageing. Nat Cell Biol 2011, 13:506-512.
51. Moerman E.J., Teng K., Lipschitz D.A., Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004, 3:379-389.
52. Eghbali M., Tomek R., Sukhatme V.P., Woods C., Bhambi B. Differential effects of transforming growth factor-beta 1 and phorbol myristate acetate on cardiac fibroblasts. Regulation of fibrillar collagen mRNAs and expression of early transcription factors. Circ Res 1991, 69:483-490.
53. Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L., Wakimoto H., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 2010, 120:3520-3529.
54. Kang H.R., Cho S.J., Lee C.G., Homer R.J., Elias J.A. Transforming growth factor (TGF)-beta1 stimulates pulmonary fibrosis and inflammation via a Bax-dependent, bid-activated pathway that involves matrix metalloproteinase-12. J Biol Chem 2007, 282:7723-7732.
55. Fukasawa H., Yamamoto T., Suzuki H., Togawa A., Ohashi N., Fujigaki Y., et al. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004, 65:63-74.
56. Nakamura T., Sakata R., Ueno T., Sata M., Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology 2000, 32:247-255.
57. van der Kraan P.M., Goumans M.J., Blaney Davidson E., ten Dijke P. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res 2012, 347:257-265.
58. Quan T., He T., Voorhees J.J., Fisher G.J. Ultraviolet irradiation blocks cellular responses to transforming growth factor-beta by down-regulating its type-II receptor and inducing Smad7. J Biol Chem 2001, 276:26349-26356.
59. Liu T., Warburton R.R., Guevara O.E., Hill N.S., Fanburg B.L., Gaestel M., et al. Lack of MK2 inhibits myofibroblast formation and exacerbates pulmonary fibrosis. Am J Respir Cell Mol Biol 2007, 37:507-517.
60. Takeji M., Moriyama T., Oseto S., Kawada N., Hori M., Imai E., et al. Smooth muscle alpha-actin deficiency in myofibroblasts leads to enhanced renal tissue fibrosis. J Biol Chem 2006, 281:40193-40200.
61. Wahl S.M., Hunt D.A., Wakefield L.M., McCartney-Francis N., Wahl L.M., Roberts A.B., et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 1987, 84:5788-5792.
62. Ishigame H., Zenewicz L.A., Sanjabi S., Licona-Limon P., Nakayama M., Leonard W.J., et al. Excessive Th1 responses due to the absence of TGF-beta signaling cause autoimmune diabetes and dysregulated Treg cell homeostasis. Proc Natl Acad Sci U S A 2013, 110:6961-6966.
63. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J Cell Sci 2003, 116:217-224.
64. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
65. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194:809-821.
66. Chiao Y.A., Dai Q., Zhang J., Lin J., Lopez E.F., Ahuja S.S., et al. Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet 2011, 4:455-462.
67. Leask A., Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J 2004, 18:816-827.
68. Desmouliere A., Geinoz A., Gabbiani F., Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993, 122:103-111.
69. Lakshminarayanan V., Lewallen M., Frangogiannis N.G., Evans A.J., Wedin K.E., Michael L.H., et al. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am J Pathol 2001, 159:1301-1311.
70. Sharma S., Dewald O., Adrogue J., Salazar R.L., Razeghi P., Crapo J.D., et al. Induction of antioxidant gene expression in a mouse model of ischemic cardiomyopathy is dependent on reactive oxygen species. Free Radic Biol Med 2006, 40:2223-2231.
71. Tokuda K., Kai H., Kuwahara F., Yasukawa H., Tahara N., Kudo H., et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 2004, 43:499-503.
72. Crisan M., Yap S., Casteilla L., Chen C.W., Corselli M., Park T.S., et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008, 3:301-313.
73. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75:389-397.
74. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
75. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
76. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat Rev Immunol 2008, 8:523-532.
77. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011, 6:457-478.
78. Constantin G., Marconi S., Rossi B., Angiari S., Calderan L., Anghileri E., et al. Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009, 27:2624-2635.
79. Gonzalez M.A., Gonzalez-Rey E., Rico L., Buscher D., Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009, 136:978-989.
80. Lee R.H., Seo M.J., Reger R.L., Spees J.L., Pulin A.A., Olson S.D., et al. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 2006, 103:17438-17443.
81. Horton J.A., Hudak K.E., Chung E.J., White A.O., Scroggins B.T., Burkeen J.F., et al. Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells 2013, 31:2231-2241.
82. Ueno T., Nakashima A., Doi S., Kawamoto T., Honda K., Yokoyama Y., et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-beta1 signaling. Kidney Int 2013, 84:297-307.
83. Waterman R.S., Tomchuck S.L., Henkle S.L., Betancourt A.M. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS ONE 2010, 5:e10088.
84. McGettrick H.M., Buckley C.D., Filer A., Rainger G.E., Nash G.B. Stromal cells differentially regulate neutrophil and lymphocyte recruitment through the endothelium. Immunology 2010, 131:357-370.
85. Roca H., Varsos Z.S., Sud S., Craig M.J., Ying C., Pienta K.J. CCL2 and interleukin-6 promote survival of human CD11b+peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 2009, 284:34342-34354.
86. Sakai N., Wada T., Furuichi K., Shimizu K., Kokubo S., Hara A., et al. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. J Leukoc Biol 2006, 79:555-563.
87. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
88. Yu Q., Vazquez R., Zabadi S., Watson R.R., Larson D.F. T-lymphocytes mediate left ventricular fibrillar collagen cross-linking and diastolic dysfunction in mice. Matrix Biol 2010, 29:511-518.
89. Stawski L., Han R., Bujor A.M., Trojanowska M. Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis. Arthritis Res Ther 2012, 14:R194.
90. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
91. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
92. Mazhari R., Hare J.M. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat Clin Pract Cardiovasc Med 2007, 4(Suppl. 1):S21-S26.
93. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
94. Ueha S., Shand F.H., Matsushima K. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol 2012, 3:71.
95. Kong P., Christia P., Saxena A., Su Y., Frangogiannis N.G. Lack of specificity of Fibroblast Specific Protein (FSP)1 in cardiac remodeling and fibrosis. Am J Physiol Heart Circ Physiol 2013, 305:H1363-H1372.
96. Eghbali M., Eghbali M., Robinson T.F., Seifter S., Blumenfeld O.O. Collagen accumulation in heart ventricles as a function of growth and aging. Cardiovasc Res 1989, 23:723-729.
97. Issa R., Zhou X., Constandinou C.M., Fallowfield J., Millward-Sadler H., Gaca M.D., et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-1808.
98. Dewald O., Frangogiannis N.G., Zoerlein M.P., Duerr G.D., Taffet G., Michael L.H., et al. A murine model of ischemic cardiomyopathy induced by repetitive ischemia and reperfusion. Thorac Cardiovasc Surg 2004, 52:305-311.
99. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996, 65:241-269.
100. Moores S.L., Schaber M.D., Mosser S.D., Rands E., O'Hara M.B., Garsky V.M., et al. Sequence dependence of protein isoprenylation. J Biol Chem 1991, 266:14603-14610.
101. Haudek S.B., Gupta D., Dewald O., Schwartz R.J., Wei L., Trial J., et al. Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc Res 2009, 83:511-518.
102. Nagueh S.F., Ommen S.R., Lakkis N.M., Killip D., Zoghbi W.A., Schaff H.V., et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001, 38:1701-1706.
103. Bustin S.A., Benes V., Garson J.A., Hellemans J., Huggett J., Kubista M., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009, 55:611-622.